Opus Genetics (NASDAQ:IRD) President Benjamin Yerxa Sells 7,470 Shares of Stock

Opus Genetics, Inc. (NASDAQ:IRD) President Benjamin Yerxa sold 7,470 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $5.24, for a total transaction of $39,142.80. Following the completion of the sale, the president directly owned 711,535 shares of the company’s stock, valued at $3,728,443.40. The trade was a 1.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Opus Genetics Stock Performance

Shares of IRD opened at $5.12 on Tuesday. The stock has a market capitalization of $365.57 million, a PE ratio of -6.24 and a beta of 0.52. The company has a 50 day moving average price of $4.70 and a 200-day moving average price of $3.09. Opus Genetics, Inc. has a fifty-two week low of $0.81 and a fifty-two week high of $5.81.

Opus Genetics News Roundup

Here are the key news stories impacting Opus Genetics this week:

• Neutral Sentiment: Management will present at several ophthalmology and industry conferences in May 2026, maintaining visibility with investors and the research community; this is routine corporate outreach rather than an immediate clinical readout. Opus Genetics to Participate in Leading Medical Conferences in May 2026
• Negative Sentiment: Multiple insiders sold stock on April 23rd (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa, and others). Combined sales total tens of thousands of shares at roughly $5.18–$5.24 per share. While the company discloses these were sales to cover tax withholding on vested awards (reducing the likelihood of a signal of loss of confidence), clustered insider selling can pressure the share price and likely contributed to today’s weakness. SEC filings: CEO sale CEO Form 4, CFO sale CFO Form 4, other insider filings available in SEC disclosures.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC increased its stake in Opus Genetics by 42.9% during the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after purchasing an additional 1,435,407 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Opus Genetics during the 4th quarter valued at approximately $5,463,000. Millennium Management LLC acquired a new position in Opus Genetics during the 4th quarter valued at approximately $4,025,000. Mink Brook Asset Management LLC increased its stake in Opus Genetics by 34.5% during the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after purchasing an additional 427,684 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Opus Genetics by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock valued at $2,214,000 after purchasing an additional 349,825 shares in the last quarter. Institutional investors and hedge funds own 14.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Craig Hallum set a $9.00 target price on shares of Opus Genetics and gave the company a “buy” rating in a research report on Wednesday, March 11th. Cantor Fitzgerald assumed coverage on shares of Opus Genetics in a research report on Monday, March 30th. They set an “overweight” rating and a $15.00 target price for the company. Oppenheimer assumed coverage on shares of Opus Genetics in a research report on Monday, March 16th. They set an “outperform” rating and a $10.00 target price for the company. Chardan Capital increased their target price on shares of Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Opus Genetics currently has a consensus rating of “Moderate Buy” and an average price target of $10.11.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.